Nasdaq

Jasper: First patient dosed in ETESIAN clinical study of briquilimab in asthma

Jasper Therapeutics (JSPR), announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating The ...
Seeking Alpha

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

The presentation slides and a link to the live and archived webcast will also be available on the Events & News – Events page of Jasper's Investor Relations website. About Jasper Jasper is a ...
Enid News & Eagle

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of ...

“Dosing of the first patient in our ETESIAN study in asthma is a significant milestone, marking our third clinical program evaluating briquilimab in an inflammatory disease driven by unwanted mast ...
Seeking Alpha

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...